Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 12, 2026

Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata
07:58

Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata

Published on: November 23, 2017

Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report.

Francois G Kamar1, Victor F Kairouz, Alain N Sabri

  • 1Division of Hematology & Oncology, Clemenceau Medical Center, City Center Building, Suite 3 A, Avenue Nouvelle, P,O, Box 1076, Beirut, Jounieh, Lebanon. kamars@idm.net.lb.

Clinical Sarcoma Research
|April 6, 2013
PubMed
Summary

Dermatofibrosarcoma protuberans (DFSP) is a rare skin tumor that often recurs after surgery. This case highlights Sorafenib as a novel treatment for recurrent DFSP that resisted other therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Pitfalls in anatomic pathology and clinical oncology: a case of misdiagnosed pulmonary Ewing sarcoma as SCLC.

Frontiers in oncology·2025
Same author

Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature.

Discover oncology·2025
Same author

Autosomal genetics and Y-chromosome haplogroup L1b-M317 reveal Mount Lebanon Maronites as a persistently non-emigrating population.

European journal of human genetics : EJHG·2020
Same author

A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen.

Brain sciences·2020
Same author

Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.

Clinical neurology and neurosurgery·2019
Same author

<sup>18</sup>F-fluoro-2-deoxyglucose positron emission-computed tomography in a rare cutaneous form of Rosai-Dorfman disease: A case report.

Molecular and clinical oncology·2018

Area of Science:

  • Oncology
  • Dermatology
  • Surgical Pathology

Background:

  • Dermatofibrosarcoma protuberans (DFSP) is a rare, locally invasive, slow-growing soft tissue sarcoma.
  • DFSP typically arises in the subcutaneous tissue and is characterized by frequent recurrences after surgical excision, despite its low metastatic potential.

Observation:

  • A case of highly recurrent and locally invasive DFSP is presented.
  • The patient's tumor demonstrated resistance to standard treatment modalities, including postoperative radiation therapy and imatinib.

Findings:

  • Successful treatment of refractory, recurrent DFSP was achieved using Sorafenib.
  • Sorafenib demonstrated an unprecedented and significant response in this challenging DFSP case.

Implications:

Related Experiment Videos

Last Updated: May 12, 2026

Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata
07:58

Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata

Published on: November 23, 2017

  • Sorafenib represents a promising therapeutic option for advanced or refractory DFSP.
  • This finding may guide future treatment strategies for patients with difficult-to-treat DFSP.
  • Further research is warranted to explore the efficacy and mechanisms of Sorafenib in DFSP treatment.